CN107108587B - 醛固酮合成酶抑制剂 - Google Patents

醛固酮合成酶抑制剂 Download PDF

Info

Publication number
CN107108587B
CN107108587B CN201580053796.XA CN201580053796A CN107108587B CN 107108587 B CN107108587 B CN 107108587B CN 201580053796 A CN201580053796 A CN 201580053796A CN 107108587 B CN107108587 B CN 107108587B
Authority
CN
China
Prior art keywords
compound
alkyl
heterocyclyl
optionally substituted
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580053796.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN107108587A (zh
Inventor
K·R·霍恩伯格
K·M·迈耶斯
P·A·尼莫托
S·瑟普伦南特
于辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54352516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107108587(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN107108587A publication Critical patent/CN107108587A/zh
Application granted granted Critical
Publication of CN107108587B publication Critical patent/CN107108587B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201580053796.XA 2014-10-15 2015-10-14 醛固酮合成酶抑制剂 Active CN107108587B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064234P 2014-10-15 2014-10-15
US62/064,234 2014-10-15
PCT/US2015/055421 WO2016061161A1 (en) 2014-10-15 2015-10-14 Aldosterone synthase inhibitors

Publications (2)

Publication Number Publication Date
CN107108587A CN107108587A (zh) 2017-08-29
CN107108587B true CN107108587B (zh) 2020-05-22

Family

ID=54352516

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580053796.XA Active CN107108587B (zh) 2014-10-15 2015-10-14 醛固酮合成酶抑制剂

Country Status (33)

Country Link
US (1) US9745289B2 (enExample)
EP (1) EP3207039B1 (enExample)
JP (1) JP6279812B2 (enExample)
KR (1) KR102441634B1 (enExample)
CN (1) CN107108587B (enExample)
AP (1) AP2017009829A0 (enExample)
AR (1) AR102266A1 (enExample)
AU (1) AU2015333611B2 (enExample)
CA (1) CA2964754C (enExample)
CL (1) CL2017000827A1 (enExample)
CO (1) CO2017003305A2 (enExample)
CY (1) CY1121650T1 (enExample)
DK (1) DK3207039T3 (enExample)
EA (1) EA031766B1 (enExample)
ES (1) ES2724555T3 (enExample)
HR (1) HRP20190896T1 (enExample)
HU (1) HUE043783T2 (enExample)
IL (1) IL251200B (enExample)
LT (1) LT3207039T (enExample)
ME (1) ME03381B (enExample)
MX (1) MX369025B (enExample)
NZ (1) NZ729688A (enExample)
PE (1) PE20170696A1 (enExample)
PH (1) PH12017500595B1 (enExample)
PL (1) PL3207039T3 (enExample)
PT (1) PT3207039T (enExample)
RS (1) RS58651B1 (enExample)
SG (1) SG11201701850UA (enExample)
SI (1) SI3207039T1 (enExample)
TR (1) TR201907755T4 (enExample)
TW (1) TWI731842B (enExample)
UA (1) UA118717C2 (enExample)
WO (1) WO2016061161A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9890171B2 (en) * 2014-12-02 2018-02-13 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
EP3562487B1 (en) * 2016-12-29 2023-11-29 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
JP7530384B2 (ja) 2019-05-01 2024-08-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング （ｒ）－（２－メチルオキシラン－２－イル）メチル ４－ブロモベンゼンスルホネート
CN116438200A (zh) 2020-09-10 2023-07-14 普雷西里克斯公司 针对fap的抗体片段
TW202339719A (zh) 2021-12-14 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療慢性腎臟病之醛固酮合成酶抑制劑
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
JP2025517625A (ja) 2022-05-02 2025-06-10 プレシリックス・ナームローゼ・ベンノートシヤープ プレターゲティング
CN121181527A (zh) * 2024-06-21 2025-12-23 江苏豪森药业集团有限公司 双稠环类化合物、及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042477A1 (en) * 2008-10-07 2010-04-15 Schering Corporation Benzodioxan analogues as alpha2c adrenergic receptor modulators
CN102803217A (zh) * 2009-05-15 2012-11-28 诺瓦提斯公司 作为醛固酮合酶抑制剂的芳基吡啶
WO2014055595A1 (en) * 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR088989A1 (es) * 2011-11-30 2014-07-23 Hoffmann La Roche Derivados biciclicos de dihidroisoquinolin-1-ona
BR112015019836A2 (pt) * 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
JP6067181B2 (ja) * 2013-04-30 2017-01-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬
HUE039981T2 (hu) * 2014-07-24 2019-02-28 Boehringer Ingelheim Int Aldoszteron szintáz inhibitorok

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042477A1 (en) * 2008-10-07 2010-04-15 Schering Corporation Benzodioxan analogues as alpha2c adrenergic receptor modulators
CN102803217A (zh) * 2009-05-15 2012-11-28 诺瓦提斯公司 作为醛固酮合酶抑制剂的芳基吡啶
WO2014055595A1 (en) * 2012-10-05 2014-04-10 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitiors related applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
In Vivo Active Aldosterone Synthase Inhibitors with Improved Selectivity:Lead Optimization Providing a Series of Pyridine Substituted 3,4-Dihydro-1H-quinolin-2-one Derivatives;Simon Lucas et al.;《J,Med.Chem.》;20081202;第51卷;第8077-8087页 *

Also Published As

Publication number Publication date
CO2017003305A2 (es) 2017-07-19
HRP20190896T1 (hr) 2019-07-12
PE20170696A1 (es) 2017-06-07
JP6279812B2 (ja) 2018-02-14
CN107108587A (zh) 2017-08-29
LT3207039T (lt) 2019-05-10
KR102441634B1 (ko) 2022-09-13
EA031766B1 (ru) 2019-02-28
AU2015333611B2 (en) 2020-02-06
ME03381B (me) 2020-01-20
MX2017004852A (es) 2017-06-22
AR102266A1 (es) 2017-02-15
AP2017009829A0 (en) 2017-03-31
RS58651B1 (sr) 2019-05-31
EP3207039B1 (en) 2019-03-06
UA118717C2 (uk) 2019-02-25
MX369025B (es) 2019-10-25
SG11201701850UA (en) 2017-04-27
TWI731842B (zh) 2021-07-01
WO2016061161A1 (en) 2016-04-21
JP2017531016A (ja) 2017-10-19
US9745289B2 (en) 2017-08-29
CL2017000827A1 (es) 2017-11-03
PH12017500595B1 (en) 2020-11-25
SI3207039T1 (sl) 2019-05-31
PL3207039T3 (pl) 2019-08-30
KR20170066651A (ko) 2017-06-14
PH12017500595A1 (en) 2017-08-30
TW201629048A (zh) 2016-08-16
EA201790830A1 (ru) 2017-09-29
BR112017005859A2 (pt) 2017-12-26
IL251200A0 (en) 2017-05-29
NZ729688A (en) 2020-05-29
CY1121650T1 (el) 2020-07-31
CA2964754A1 (en) 2016-04-21
AU2015333611A1 (en) 2017-03-23
DK3207039T3 (en) 2019-04-23
ES2724555T3 (es) 2019-09-12
IL251200B (en) 2019-05-30
HUE043783T2 (hu) 2019-09-30
PT3207039T (pt) 2019-06-04
CA2964754C (en) 2023-01-24
US20160108026A1 (en) 2016-04-21
EP3207039A1 (en) 2017-08-23
TR201907755T4 (tr) 2019-06-21

Similar Documents

Publication Publication Date Title
CN107108587B (zh) 醛固酮合成酶抑制剂
CN106232587B (zh) 二取代1,2,4-三嗪化合物
KR102248559B1 (ko) 4-아자인돌 유도체
JP6067181B2 (ja) アルドステロンシンターゼ阻害薬
KR102378648B1 (ko) 알도스테론 신타아제 억제제
TW201326127A (zh) 新穎菸鹼醯胺衍生物或其鹽
WO2016022742A1 (en) Antidiabetic bicyclic compounds
JP2014527981A (ja) アミド化合物、組成物およびその用途
JP6707084B2 (ja) アルドステロンシンターゼ阻害薬
AU2015220553B2 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
JP6914974B2 (ja) 腎疾患、心血管疾患、および線維性障害の治療に有用な二環式イミダゾール誘導体
CN115052860B (zh) 胶原蛋白1翻译抑制剂和其使用方法
TW201920107A (zh) 作為ttx-s阻斷劑之雙芳氧基衍生物
CN103958473B (zh) 酰胺类化合物、组合物及其应用
WO2025184010A1 (en) N-biaryl sulfonamides as modulators of the hippo pathway
HK1243068A1 (en) Aldosterone synthase inhibitors
BR112017005859B1 (pt) Inibidores de aldosterona sintase, seus usos e sais farmaceuticamente aceitáveis e composição farmacêutica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant